Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated ...
Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...
Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants ...
Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous AdministrationKey ...
Early GO decision reached ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Key objectives achieved: ...
Investor's Business Daily on MSN
Dianthus Therapeutics has appreciated 12-fold over two years. What's going on?
Dianthus Therapeutics stock shot higher Monday after the company said it would advance its experimental CIDP treatment.
Chennai: People whose immune systems mount an unusually aggressive early response to tuberculosis may be less likely to respond well to standard drug .
EAE-induced neuroinflammation. Using immuohistochemistry, flow cytometry, and single-cell RNAseq of doublets to interrogate cell-cell interactions, the authors provide solid evidence that macrophages, ...
Learn how targeted-release budesonide treats IgA nephropathy, cutting proteinuria and slowing GFR decline with fewer steroid side effects. When are you utilizing endothelin antagonists, complement ...
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results